Selvita

Selvita FCF Yield

The Free Cash Flow Yield of Selvita (SLV.WA) as of Oct 22, 2026 is 7.20 %. In the previous year, Free Cash Flow Yield was 5.71 % — a change of 26.19% (higher).

FCF Yield

7.20 %

YoY

26.19%

Last updated:

Free Cash Flow Yield of Selvita is 2025 7.20 % . Free Cash Flow Yield of Selvita was 2024 5.71 % . It decreases by 26.19% higher compared to the previous year.

The Selvita FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
0.48 PLN
Jan 1, 2019
0.39 PLN
Jan 1, 2020
1.81 PLN
Jan 1, 2021
7.54 PLN
Jan 1, 2022
-3.29 PLN
Jan 1, 2023
0.63 PLN
Jan 1, 2024
5.71 PLN
Jan 1, 2025
7.20 PLN
The Selvita FCF Yield history
YEARFCF YieldYoY
7.20 %+26.19%
5.71 %+798.91%
0.63 %-119.29%
-3.29 %-143.63%
7.54 %+317.66%
1.81 %+365.89%
0.39 %-19.35%
0.48 %-57.27%
1.12 %-132.52%
-3.46 %+27.16%
-2.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Selvita Stock analysis

What does Selvita do? Selvita SA generates revenue through multidisciplinary solutions for drug discovery, regulatory studies, and research and development. The company provides early-stage drug discovery support, including target validation and clinical candidate selection, alongside drug testing and bioanalytical services such as method development, stability studies, and quality control testing. Its clients include pharmaceutical companies and research institutions across Europe and the United States, which rely on Selvita's expertise for comprehensive project support throughout the drug development lifecycle. The firm's services span the entire drug discovery process, from initial target identification to preclinical research and clinical candidate selection. By offering end-to-end solutions, Selvita caters to clients seeking efficient and reliable support in complex research phases. Its collaborations with European and American research institutes and universities further strengthen its position in the biotech and pharmaceutical sectors. Selvita SA's business model focuses on delivering specialized scientific services tailored to the needs of clients in drug development. The company's offerings cover all critical stages of the drug discovery process, ensuring clients can advance their projects with minimal delays. This approach allows Selvita to maintain strong relationships with its key clients in the pharmaceutical and research communities. Selvita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Selvita stock

Free Cash Flow Yield of Selvita is 7.20 % in 2025.

Free Cash Flow Yield of Selvita changed from 5.71 % to 7.20 %, representing a 26.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Selvita since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Selvita with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Selvita

All Key Metrics — Selvita